JAK2 and myeloproliferative neoplasm: JAK2 inhibitor resistance may be mediated in part by JAK1 activation, which also functions as a critical mediator of inflammatory cytokine signaling, suggesting that JAK1 inhibition may be effective in MPN and/or enhance the efficacy of JAK2 inhibition [140,177].